Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation
HONG KONG, June 13, 2016 /CNW/ -- Hutchison China MediTech (LONDON STOCK EXCHANGE: HCM, NASDAQ: HCM) based in China, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Today announced that their June 10 presentation from Chief Executive Officer, Christian Hogg, is now available for on-demand viewing in the dbVIC Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference.
Hutchison China MediTech presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the virtual trade booth in the Exhibits section of the event.
Recent Company Highlights
- Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer
- Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689
- Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market
- Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients
About Hutchison China MediTech
Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: http://www.chi-med.com
SOURCE Hutchison China MediTech
For further information: Hutchison China MediTech, Mr. Christian Hogg, Chief Executive Officer, [email protected], +852 2121 8200, http://www.chi-med.com